Fenbufenの上気道炎症に対する二重盲検臨床試験

概要

論文の詳細を見る
In our present studies, we investigated the therapeutic efficacy and safety of fenbufen (FB) (Lederle) for the inflammation of upper respiratory tract using a double blind technique.In a pilot study, FB 900mg/day was compared with oxyphenbutazone (OB) 600mg/day and lactose placebo (PL), and improvement rates with FB were the highest among the three. FB was significantly superior to PL.In a subsequent primary study, FB was administered in a dose of 600mg/day and OB, as a control, 600mg/day. The results of the study showed that FB significantly surpassed OB in overall evaluation, and, in 12 out of the 19 symptoms evaluated, FB demonstrated higher improvement rates than those of OB.
耳鼻咽喉科臨床学会の論文